Crossmark

The albumin-bilirubin (ALBI) model in hepatocellular carcinoma (HCC) may better predict hepatic failure in patients with traditionally low-risk cirrhosis following definitive stereotactic body radiotherapy (SBRT)

Crossref DOI link: https://doi.org/10.1007/s13566-018-0354-7

Published Online: 2018-05-08

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hasan, S.

Abel, Stephen

Jan, Imraan

Uemura, Tadahiro

Thai, N.

Kirichenko, A. V.
License Information

Text and Data Mining valid from 2018-05-08
More Information

Article History

Received: 7 February 2018

Accepted: 27 April 2018

First Online: 8 May 2018

Compliance with ethical standards

:

: No funding was received for this study.

: The authors declare that they have no conflict of interest.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below